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Abstract
Background: Alterations of mitochondrial DNA (mtDNA) have been implicated in carcinogenesis. We
developed an accurate multiplex quantitative real-time PCR for synchronized determination of mtDNA
and nuclear DNA (nDNA). We sought to investigate whether mtDNA content in the peripheral blood of
breast cancer patients is associated with clinical and pathological parameters.
Methods: Peripheral blood samples were collected from 60 patients with breast cancer and 51 age-
matched healthy individuals as control. DNA was extracted from peripheral blood for the quantification
of mtDNA and nDNA, using a one-step multiplex real-time PCR. A FAM labeled MGB probe and primers
were used to amplify the mtDNA sequence of the ATP 8 gene, and a VIC labeled MGB probe and primers
were employed to amplify the glyceraldehyde-3-phosphate-dehydrogenase gene. mtDNA content was
correlated with tumor stage, menstruation status, and age of patients as well as lymph node status and the
expression of estrogen receptor (ER), progesterone receptor (PR) and Her-2/neu protein.
Results: The content of mtDNA in stage I breast cancer patients was significantly lower than in other
stages (overall P = 0.023). Reduced mtDNA was found often in post menopausal cancer group (P = 0.024).
No difference in mtDNA content, in regards to age (p = 0.564), lymph node involvement (p = 0.673), ER
(p = 0.877), PR (p = 0.763), and Her-2/neu expression (p = 0.335), was observed.
Conclusion: Early detection of breast cancer has proved difficult and current detection methods are
inadequate. In the present study, decreased mtDNA content in the peripheral blood of patients with
breast cancer was strongly associated with stage I. The use of mtDNA may have diagnostic value and
further studies are required to validate it as a potential biomarker for early detection of breast cancer.
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Background
More than 75 years since Warburg described how tumor
cells avidly consume glucose and produce lactic acid
under aerobic conditions, it still remains unclear how this
metabolic shift provides tumor cells with a growth advan-
tage[1,2]. Recent evidence has shown that tumor cells
adapt their metabolism to the microenvironment by sup-
pressing mitochondrial function rather than increasing
glycolysis [3]. In patients with mitochondrial disease,
mitochondrial function is vulnerable to damages due to
deletions, mutations or replication abnormalities of mito-
chondrial DNA (mtDNA) resulting in energy depletion
and increased susceptibility to apoptosis [4]. Addition-
ally, mtDNA alterations are correlated with various cancer
types, suggesting that the mitochondrial genome may be
a critical contributing factor in carcinogenesis. mtDNA
content has been implicated as a potential biomarker for
several cancer types [5]. Decreased mtDNA content had
been reported for renal [6], gastric [7], breast [5,8], previ-
ously-treated head and neck [9], ovarian [10] and hepatic
cancer [11-13]. In contrast, several studies have revealed
an increased mtDNA content in prostate [14], untreated
head and neck [15], thyroid [5], endometrial [16], and
pancreatic cancer [17]. Interestingly, mtDNA alterations
were also detected in bodily fluids, suggesting that
mtDNA changes might serve as sensitive early biomarker
for non-invasive detection of several types of solid cancer
including breast cancer [18].
Similarly to previous reports [5], we have shown that
mtDNA content was decreased in 82% of cancerous breast
tissues, as compared with the normal ones[19]. However,
to our best knowledge, no data exist regarding mtDNA
content in peripheral blood of breast cancer patients and
its correlation with clinical-pathological parameters. In
the present study, we measured mtDNA content from
peripheral blood samples of patients with breast cancer
using a novel multiplex quantitative real-time PCR, as pre-
viously described [20]. The association between periph-
eral blood mtDNA content and clinical-and pathological
parameters was analyzed and compared with the healthy
donors.
Methods
Sample collection
Blood samples from 60 patients with breast cancer were
taken before primary surgery. All patients were diagnosed
between 2005 and 2007 and underwent surgery at the
First Affiliated Hospital of Medical School of Xi'an Jiao
Tong University of China. 51 control samples were ran-
domly selected among individuals visiting hospitals for
regular health checks. All patients gave informed consent
for retention and analysis their blood for research purpose
according to institutional guidelines and the study was
approved by the research ethics committee of the Medical
School of Xi'an Jiao Tong University, China. Tumors were
staged according to the TNM classification (Union Inter-
nationale Contre le Cancer, UICC). None of patients
received neoadjuvant treatment or have distant metas-
tases as the time of primary surgery. Hematoxylin and
eosin staining was used for routine pathological evalua-
tion. Expression of estrogen receptor (ER), progesterone
receptor (PR) and Her-2/neu protein was determined by
immunohistochemistry. Clinical-pathological data (age,
histological grade, tumor size, lymph node status, ER-,
PR-, and Her-2/neu expression) are summarized in Table
1. The median ages of the cancer and the control group
were 49.5 ± 1.6 years and 51.0 ± 2.0 years, respectively.
DNA isolation and multiplex quantitative real-time PCR
DNA was subsequently isolated from whole blood by
phenol-chloroform extraction and ethanol precipitation
[21]. The DNA samples were divided into aliquots of 100
μl and were stored in -80°C. The ABI PRISM 7000
Sequence Detection System (Applied Biosystems, ABI)
was used to amplify the GAPDH housekeeping gene and
the mitochondrial DNA encoded ATPase (MTATP) 8 gene.
Primers and probes used for detection of GAPDH and
MTATP 8 gene sequences were: GAPDH (forward): 5'-
CCC CAC ACA CAT GCA CTT ACC; (reverse): 5'-CCT AGT
CCC AGG GCT TTG ATT; probe 5'-(MGB)-TAG GAA GGA
CAG GCA AC (VIC). Mitochondrial DNA (forward): 5'-
AAT ATT AAA CAC AAA CTA CCA CCT ACC; (reverse): 5'-
TGG TTC TCA GGG TTT GTT ATA; probe: 5'-(MGB)-CCT
CAC CAA AGC CCA TA (FAM). The real-time RT-PCR was
carried out in 25 μl of total reaction volume containing 5
μl (40 ng) of DNA, 12.5 μl of TaqMan® Universal PCR
Master Mix, 4 primers and 2 probes using a 2 minute incu-
bation at 50°C, followed by an initial denature step at
95°C for 10 minutes and 40 cycles of 1 minute at 60°C
and 15 seconds at 95°C. All samples were analyzed in
triplicate. To determine the quantities of mtDNA and
nDNA present in blood samples, the average threshold
cycle number (Ct) values of the nDNA and mtDNA were
obtained from each case. The level of mtDNA was calcu-
lated using the delta Ct (ΔCt) of average Ct of mtDNA and
nDNA (ΔCt = CtmtDNA-CtnDNA) in the same well as an
exponent of 2 (2ΔCt).
Statistical analysis
Contents of mtDNA and nDNA are given as the median,
the range and the fold difference. Receiver operating char-
acteristic (ROC) curves were generated to estimate the
sensitivity and specificity of mtDNA content. The Shapiro-
Wilk test was used to analyze the data distribution. It
showed that our data set was not normally distributed (p
= 0.000 and 0.010 for the mtDNA- and the GAPDH assay,
respectively). The two-sample Kolmogorov-Smirnov (K-
S) test was used to compare the content of mtDNA in
blood between the control- and breast cancer group. TheBMC Cancer 2009, 9:454 http://www.biomedcentral.com/1471-2407/9/454
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Spearman's rho analysis was applied to analyze the rela-
tionship of mtDNA content in peripheral blood between
the two groups. The Mann-Whitney U Test and Kruskal-
Wallis test were employed to compare mtDNA content
with clinical-pathological parameters in breast cancer
group. We converted the mtDNA content values to ranks,
and then did one-way ANOVA on the ranks in order to use
the Tukey post-hoc procedure for the pairwise compari-
ons of mtDNA content in relation to tumor stage. Differ-
ences were considered significant when p < 0.05. All
statistical analyses were performed using the SPSS version
15.0 software (SPSS Inc., Chicago, IL).
Results
Measurements of the efficiency of multiplex Assays
The specificity of the assay for detecting the mtDNA was
assessed using the mtDNA depleted 143b rho0cell line.
No positive amplification of nucleus-embedded mtDNA
sequences was obtained from the cell line using the assay
for mtDNA (data not shown). To determine the quantities
of mtDNA and nDNA present in blood samples, standard
dilution curves were generated from a human genomic
DNA with known concentrations, ranging from 3.125 ×
104 to 10 pg/μl (including 31250, 6250, 1250, 250, 50
and 10 pg/μl). We used experimental serial dilutions to
examine the amplification efficiencies for the MTAPT-8-
gene amplicon (79 bp) for representing total mtDNA, and
the GAPDH-gene amplicon (97 bp) for representing total
nDNA. The amplifications of mtDNA and nDNA on serial
dilutions showed a good correlation with comparable
efficiencies of close to 99%.
Co-extraction of mtDNA and nDNA from peripheral blood 
samples of breast cancer patients
The average Ct values of GAPDH ranged from 20.16 to
24.71 in blood samples of patients with breast cancer and
from 21.73 to 25.73 in whole blood samples of the con-
trol group, respectively. The average Ct values of MTATP 8
gene ranged from 10.65 to 21.54 in blood samples of
patients with breast cancer and from 11.78 to 14.88 in
whole blood samples of the control group, respectively. In
breast cancer patients, mtDNA content was higher than
nDNA (Table 2).
The average Ct values of GAPDH amplicon in the normal
group were correlated with those of MTATP8 gene ampli-
con (Spearman's rho Test: p < 0.001, r = 0.496) (Figure 1).
In contrast, no significant correlation was detected in can-
cerous group (p > 0.05, r = 0.148) (Figure 2), suggesting
an alteration of the relationship between nDNA and
mtDNA in blood samples of breast cancer patients.
mtDNA in whole blood samples from the normal and 
breast cancer group
We used a formula of 2ΔCt to calculate the content of
mtDNA in whole blood. The area under the ROC curve for
Table 1: Patient's data and correlation between levels of mtDNA in peripheral blood of patients with breast cancer and clinical-
pathological parameters
Variable Number mtDNA content
Median (Range)
P value
Age (years)
<50 30 525.96 (0.47 - 35241.80) *0.564
≥50 30 660.59 (0.39 - 27175.14)
Menopausal status
pre 37 1365.30 (0.47 - 35241.80) *0.024
post 23 262.29 (0.39 - 5166.60)
Lymph-node status
negative 29 668.60 (4.23 - 27175.14) *0.673
positive 31 436.55 (0.39 - 35241.80)
Stage
I 20 196.94 (0.47 - 6841.04) **0.023
II 20 1656.18 (10.89 - 35241.80)
III-IV 20 572.71 (0.39 - 4956.14)
ER
positive 29 657.11 (0.39 - 35241.80) *0.877
negative 31 376.11 (0.47 - 27175.14)
PR
positive 36 654.85 (4.23 - 27175.14) *0.763
negative 24 669.09 (0.39 - 35241.80)
Her2/neu protein
positive 32 242.96 (0.39 - 35241.80) *0.335
negative 28 824.78 (10.89 - 27175.14)
*P values are obtained by using the Mann-Whitney U test. ** P values are obtained by using one-way ANOVA on the rank followed by the Tukey 
test.BMC Cancer 2009, 9:454 http://www.biomedcentral.com/1471-2407/9/454
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the mtDNA content was 0.76 (95% confidence interval,
0.67-0.87) with sensitivity of 73 and specificity of 78%. A
10.43 cycle difference in normal group and a 9.36 cycle
difference in cancerous group were found by calculating
the ΔCt values between GAPDH amplicon and MTATP 8
gene amplicon. The ΔCt values between normal and can-
cerous group showed a 1.07 cycle difference (ΔΔCt) (p <
0.01) as shown in Table 2.
Relationship between decreased content of mtDNA and 
clinical parameters
mtDNA content was compared with various clinical and
pathological parameters of breast cancer patients such as
age, menopause, TNM stage, lymph node status, ER-, PR-
and Her-2/neu expression (Table 1). No significant differ-
ence in mtDNA content of peripheral blood was observed
in regards to age, lymph node involvement, ER-, PR- and
Her-2/neu expression (Table 1). However, the mtDNA
content was significantly lower in stage 2 than in the other
stages (Table 1 and Figure 3, overall P = 0.023, I vs II, P =
0.018). The decreased mtDNA content in breast cancer
patients was also correlated to menopausal status of beast
cancer patients (Table 3 and Figure 4, P = 0.024). Signifi-
cant decreased mtDNA content of peripheral blood was
found in postmenopausal patients with cancer compared
with that in postmenopausal normal group (Figure 4, P =
0.019).
Table 2: Level of mtDNA content in peripheral blood of the control- and breast cancer groups
Normal
N = 50
Breast Cancer
N = 60
Change
(ΔΔ Ct)
P value
ΔCt (CtnDNA - CtmtDNA)
Median 10.43 9.36
Range 6.07-12.03 -1.37-15.11 1.07
mtDNA content
Median 1374.79 654.85 *p = 0.009
Range 66.95-4182.07 0.39-35241.80 2.10
Correlation
(CtnDNA vs CtmtDNA)r  =  0 . 4 9 6
**p = 0.000
r = 0.148
**p = 0.259
* Kolmogorov-Smirnov (K-S) test; ** Spearman's rho test.
Correlation of nDNA content and mtDNA content in  peripheral blood in normal group Figure 1
Correlation of nDNA content and mtDNA content in 
peripheral blood in normal group. Scatter plot illus-
trates the Ct values of GAPDH amplicon (X axis) against the 
Ct values of MTATP 8 amplicon (Y axis) in blood samples of 
normal group (n = 50). The correlation rate is highly signifi-
cant (p = 0.0001) according the Spearman' rho test.
nDNA Ct value in normal group
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Correlation of nDNA content and mtDNA content in  peripheral blood in breast cancer group Figure 2
Correlation of nDNA content and mtDNA content in 
peripheral blood in breast cancer group. Scatter plot 
illustrates the Ct values of GAPDH amplicon (X axis) against 
the Ct values of MTATP 8 amplicon (Y axis) in blood samples 
of breast cancer group (n = 60). The correlation rate is not 
significant (p = 0.259) according the Spearman' rho test.
nDNA Ct value in cancer group
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Discussion
mtDNA is vulnerable to DNA damage due to: a) the lack
of protective histones; b) insufficient DNA repair capacity;
c) a high rate of reactive oxygen species generation in
mitochondria [22]. Mitochondria play an essential role in
cellular energy metabolism, free radical generation and
programmed cell death [23]. According to these character-
istics and functions of mtDNA, it has been noted that
alterations found in mtDNA could be involved at the early
stage of carcinogenesis [24] and may play an important
role in mitochondrial dysregulation and cancer develop-
ment [9]. In addition, previous studies have suggested the
potential use of mtDNA as biomarker for the early detec-
tion of cancer [25]. Low mtDNA content was identified in
tumors specimens of breast cancer at an early stage, sug-
gesting that it might be essential in early progression of
breast cancer, most probably by impairing the oxidative
phosphorylation or mitochondrial bioenergetics [8].
Jiang et al. showed a significantly increased mtDNA con-
tent in the saliva with advanced stage [15]. The change of
mtDNA may therefore be important for cancer initiation
and progression [14]. However, few studies have
addressed the deletion and mutation of mtDNA in tumor
Table 3: The correlation between the menopausal status and the levels of mtDNA in peripheral blood of breast cancer and normal 
groups
Variable Number mtDNA content
Median (Range)
P value
Cancer
Menopausal status
pre 37 1365.30 (0.47-35241.80) 0.024
post 23 262.29 (0.39-5166.60)
Normal
Menopausal status
pre 31 1443.15 (136.71-4182.07) 0.396
post 20 1097.52 (66.95-3808.48)
P values are obtained by using the Mann-Whitney U Test.
Box plot analysis illustrating levels of mtDNA in peripheral  blood of normal group and breast cancer groups according  the stage ofcarcinomas Figure 3
Box plot analysis illustrating levels of mtDNA in 
peripheral blood of normal group and breast cancer 
groups according the stage ofcarcinomas. The quanti-
tative mtDNA content (as described in the text) is shown on 
the Y axis. The mtDNA content in peripheral blood of stage I 
breast cancers is significant lower than in the other stages 
according the One-way ANOVA on the ranks (*P = 0.018). 
Horizontal lines: group medians; boxes: 25--75% quartiles,, 
range, peak and minimum.
*
N= 20 20 20
Overall P = 0.023
1.00
Box plot analysis illustrating levels of mtDNA in peripheral  blood of breast cancer patients according the menopausal  status Figure 4
Box plot analysis illustrating levels of mtDNA in 
peripheral blood of breast cancer patients according 
the menopausal status. The quantitative mtDNA content 
is shown on the Y axis. The mtDNA content in peripheral 
blood of postmenopausal patients is significant lower than 
premenopausal patients according the Mann-Whitney U Test 
(* P = 0.024, NS: not significant); Horizontal lines: group 
medians; boxes: 25--75% quartiles, range, peak and minimum.
37 23 31 20
*
NS
N=
Cancer Normal
1.00BMC Cancer 2009, 9:454 http://www.biomedcentral.com/1471-2407/9/454
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tissues and blood of patients with breast cancer and the
published results were inconsistent. Recent studies did
not detect mtDNA mutations and deletions in the blood
of women with breast cancer, implying that the mtDNA
deletion and mutation play a minor role in breast carcino-
genesis [26-28]. Furthermore, no previous data exist
regarding the content of mtDNA in peripheral blood of
breast cancer patients. In our study, we used MTATP 8
gene, a mitochondrial DNA encoded ATPase, to analyze
the quantities of mtDNA in peripheral blood. We show
that mtDNA content in whole blood from breast cancer
patients significantly decreased in stage I breast cancer
samples as compared with more advanced stages. This
suggests that breast cancer cells depleted a high amount of
mtDNA in the circulating system. mtDNA depletion could
affect progression and metastasis of cancer cells by pre-
venting apoptosis and generating cancer-related proteins
[22]. The high frequency of mtDNA alterations in cancer
and their presence in the stages I disease could possibly be
exploited as clinical markers for early cancer detection
[29]. Interestingly, Barrientos et al. reported that an
increase in mtDNA content might be a compensatory
response for decline in respiratory function [30]. So, that
was why our results showed that mtDNA content firstly
decreased at stage I and subsequently increased by the
normal levels at stage II and stage III-IV.
A previous quantitative analysis suggested that the
mtDNA content did not change with age of patients [31].
Similarly, our results displayed no significant difference
between the decreased mtDNA content and age of
patients. However, a recent report showed that the
reduced copy number in mtDNA was more frequent in
patients older than 50 years of age [8]. The relationship,
therefore, between mtDNA content and patient's age
needs further investigation. mtDNA circulates in periph-
eral blood not only in a cell-free form but also in a parti-
cle-associated form [32]. Mehra et al. showed that
circulating concentrations of genomic DNA and mtDNA
were not correlated with each other in plasma, probably
due to the different compartmentalization and degrada-
bility of mtDNA and nDNA in cancers [33]. In line to this
report, our results revealed no significant association
between mtDNA content and nDNA content in peripheral
blood from breast cancer patients.
The association between mtDNA content in peripheral
blood and patients' age or clinical-pathological parame-
ters was determined. No correlations between mtDNA
content in peripheral blood and those parameters of
breast cancer could be observed. Yu et al. have previously
shown reduced mtDNA content to have a significant cor-
relation with ER or PR status [8,19]. Endocrine treatment
is essential for premenopausal as well as postmenopausal
breast cancer patients [34]. Several studies showed that
mitochondria respiration varies during the menstrual
cycle and is correlated with pregnancy[35,36]. In our
study, reduced mtDNA content inclined to have a signifi-
cant correlation with menopausal status of breast cancer
patients. However, whether reduced mtDNA in peripheral
blood of breast cancer patients could potentially affect the
outcome of endocrine treatment of breast cancer remains
unknown.
Conclusion
Our data suggest that the decrease of mtDNA content in
peripheral blood of patients with breast cancer may have
diagnostic and prognostic value. Decreased mtDNA con-
tent is associated with the menopausal status of patients
and TNM stage of cancers. The use of mtDNA may have
diagnostic and prognostic value and further studies are
required to validate it as a potential biomarker for early
detection of breast cancer.
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